Start: June 1, 2018
End: December 2025
Enrollment: 105
Tau is a protein that accumulates abnormally in the brains of people with Alzheimer's disease and other dementias. This study will use the new radioactive tracer 18F-MK-6240 in positron emission tomography (PET) scanning to detect tau pathology in older adults who are cognitively healthy and mildly cognitively impaired. Researchers will examine the interactions between tau levels and performance on cognitive tasks, neural activation patterns using functional MRI brain scans, and other cognitive and behavioral measures. The study also aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Minimum Age: 55 Years
Maximum Age: 90 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
New York | |
---|---|
Columbia University Medical Center
New York, NY 10032
Recruiting
Ashley Mensing, BS |
Lead: Yaakov Stern
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT03372317
An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health